Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: The AGATE Study;Efficacité et la tolérance de la lercanidipine ne sont pas liées à l'âge des patients hypertendus: Étude AGATE

Annales de Cardiologie et d'Angeiologie

Volumn 53, Issue 3, 2004, Pages 123-130

  Poncelet, P ^a   Ribstein, J ^b   Goullard, L ^a   Bassous, M ^c   Scart Gres C ^c   Clerson, P ^d  

^a Polyclinique de Henin Beaumont   (France)

^b Service de Medecine Interne   (France)

^c Laboratoire Bouchara Recordati   (France)

^d Orgamétrie Wasquehal ^*  (France)

Author keywords

d mes; ge; Age; Dihydropyridine; Efficacit ; Efficacy; Oedema; Tol rance; Tolerability

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; LERCANIDIPINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; AUTOMATION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DEVICE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PULSE PRESSURE; TITRIMETRY;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIHYDROPYRIDINES; EDEMA; FEMALE; HUMANS; HYPERTENSION; LEG; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 2342606445     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ancard.2004.03.004     Document Type: Article

References (18)

1. Pahor M., Psaty B.M., Alderman M.H., Applegate W.B., Williamson J.D., Cavazzani C., Furber C.D. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 356:2000;1949-1954
2. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High blood pressure. 8:1999;92-101
3. Erne P., Bolli P., Bertel O., Hulthen L., Kiowski W., Muller F.B., Buhler F. Factors influencing the hypotensive effects of calcium antagonists. Hypertension. 5:(suppl 11):1983;97-102
4. Resnick L.M., Nicholson J.P., Laragh J.H. Calcium, the renin-aldosterone system, and the hypotensive response to Nifedipine. Hypertension. 10:1987;254-258
5. Bobrie G., Chatellier G., Genes N., Clerson P., Vaur L., Vaisse B., Mallion J.M. L'automesure tensionnelle a une valeur pronostique supérieure à celle de la mesure conventionnelle: résultats de l'étude SHEAF (Self Measurement of blood pressure at Home in the Elderly: Assessment and Follow-up). Abstract, Journées HTA Arch Mal Cœur. 95:2002;01
6. Ohkubo T., Imai Y., Tsuji I., et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 16:1998;971-975
7. Asmar R., Zanchetti A. on behalf of the organizing committee and participants. Guidelines for the use of self-blood pressure monitoring: a summary report of the first international consensus conference. J Hypertens. 18:2000;493-508
8. Van Hamersvelt H.W., Kloke H.J., de Jong D.J., Koene R.A.P., Huysmans F., Th M. Oedema formation with the vasodilatators nifedipine and diazoxide: direct local effect on sodium retention? J Hypertens. 14:1996;1041-1045
9. Weir M.R., Rosenberger C., Fink J.C. Pilot Study to Evaluate a Water Displacement Technique to Compare effects of Diuretics and ACE Inhibitors to Alleviate Lower Extremity. Oedema due to dihydropyridine calcium antagonists. Am J Hypertens. 14:2001;963-968
10. Gustafsson D. Microvascular mechanisms involved in calcium antagonist oedema formation. J. Cardiovasc Pharmacol. 10:(suppl 1):1987;S 121-S131
11. Guazzi M.D., De Cesare N., Galti C. Calcium-channel blockage with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Hypertension. 70:1984;279-284
12. Lacolley P., Poitevin P., Koen R., Levy B.I. Differents effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats. J. Hypertens. 16:1998;349-355
13. Ribstein J. Caractérisation clinique de la lercanidipine. La lettre du pharmacologue. 15:(Suppl 3):2001;17-21
14. Borghi C., Prandin M.G., Dormi A., Bacchetti S., Esposti D.D., Ambrosioni E. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients. 10th European meeting on hypertension Goteborg:2000;. Abstract
15. Leonetti G., Magnani B., Pessina A.C., Rappelli A., Trimarco B., Zanchetti A. on behalf of the COHORT Study group. Tolerability of long-term treatment with Lercarnidipine vs Amlodipine and Lacidipine in Elderly Hypertensives. Am J Hypertens. 15:2002;932-940
16. ALLHAT Collaborative research group Major outcomes in High-Risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2891-2897
17. Pedrinelli R., Dell'Omo G., Nuti M., Menegato A., Balbarini A., Mariani M. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine vs lercanidipine in hypertensive patients. Journal of Hypertension. 21:(10):2003;1969-1973
18. Lund-Johansen P., Stranden E., Helberg S., Wessel-Aas T., Risberg K., Rønnevik P.K., Istad H., Madsbu S. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 21:2003;1003-1010